APAC Chemotherapy-Induced Peripheral Neuropathy (CIPN) Patient Pool Analysis, Market Size and Market Forecast Report 2024-2034
April 30, 2024 07:44 ET
|
Research and Markets
Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "Chemotherapy-Induced Peripheral Neuropathy (CIPN) Patient Pool Analysis, Market Size and Market Forecast APAC - 2034" report has been added to ...
Global Diabetic Neuropathy Treatment (Peripheral, Autonomic, NSAIDs, Capsaicin, Opioid) Market Size, Share & Trends Analysis Report 2024-2030
April 22, 2024 10:20 ET
|
Research and Markets
Dublin, April 22, 2024 (GLOBE NEWSWIRE) -- The "Global Diabetic Neuropathy Treatment Market Size, Share & Trends Analysis Report by Disorder Type (Peripheral Neuropathy, Autonomic Neuropathy),...
Peripheral Neuropathy Market Size Worth USD 8.54 Billion in 2032 | Emergen Research
January 22, 2024 10:57 ET
|
Emergen Research
Vancouver, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The global peripheral neuropathy market size was USD 3.61 Billion in 2022 and is expected to register a revenue CAGR of 9.0% during the forecast period....
Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes Patients
June 28, 2023 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of two large studies that support the clinical utility of DPNCheck screening in people...
Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)
May 31, 2023 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted publication of an abstract describing partial results from a NIH-funded, multi-site randomized controlled trial...
NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy
January 23, 2023 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the commercial availability of DPNCheck 2.0, the Company's latest point-of-care device that...
Over 20 Million Suffer From Peripheral Neuropathy, St. Pete Medical Group Aims to Help
December 14, 2022 12:30 ET
|
St. Pete Medical Group
ST. PETERSBURG, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- St. Pete Medical Group and Clearwater Medical Group were featured on 10 Tampa Bay's Great Day Live. Dr. Alex Spinoso announced their mission...
Global Peripheral Neuropathy Treatment Market to Surpass US$ 2,425.9 Million by 2030, Says Coherent Market Insights (CMI)
June 21, 2022 08:40 ET
|
CMI
Seattle, June 21, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global peripheral neuropathy treatment market is estimated to be valued at US$ 1,795.10 million in 2022 and is...
CIPN Market: 5.4% CAGR for Chemotherapy-Induced Peripheral Neuropathy Market Worth $1.17 Billion, Globally, by 2028: The Insight Partners
May 26, 2022 15:07 ET
|
The Insight Partners
New York, May 27, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Chemotherapy-Induced Peripheral Neuropathy Market Forecast to 2028 - COVID-19 Impact and Global...
Neuropathix, Inc. Announces Publication of Validated Preclinical Studies on KLS-13019 in the British Journal of Pharmacology
May 06, 2021 09:00 ET
|
Neuropathix, Inc.
DOYLESTOWN, Pa., May 06, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today the...